Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit, Allergan Expand Drug-Discovery Alliance; ExonHit Pockets $2M

NEW YORK, May 17 (GenomeWeb News) - ExonHit Therapeutics and Allergan have extended a drug-discovery and -development collaboration for neurodegenerative diseases, pain, and ophthalmology, the firms said today.


Terms of the expanded alliance call for Allergan to pay ExonHit $2 million.


The original collaboration was initiated in 2003. It called for ExonHit to help Allergen discover and develop drug targets by analyzing "RNA splicing events."

Under the terms of the collaboration, ExonHit receives financial support in the form of on-going R&D payments as well as payments for drug candidates achieving certain development milestones.


Additionally, ExonHit is set to receive co-development and co-commercialization options in therapeutic areas outside of Allergan's key strategic areas and royalties. Profit-sharing on commercialized drugs is also an option, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.